CL2021002461A1 - Péptido, anticuerpo y tcr que se unen al mismo, célula hospedadora, linfocito t activado, composición farmacéutica que los comprende, y sus usos en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) - Google Patents
Péptido, anticuerpo y tcr que se unen al mismo, célula hospedadora, linfocito t activado, composición farmacéutica que los comprende, y sus usos en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093)Info
- Publication number
- CL2021002461A1 CL2021002461A1 CL2021002461A CL2021002461A CL2021002461A1 CL 2021002461 A1 CL2021002461 A1 CL 2021002461A1 CL 2021002461 A CL2021002461 A CL 2021002461A CL 2021002461 A CL2021002461 A CL 2021002461A CL 2021002461 A1 CL2021002461 A1 CL 2021002461A1
- Authority
- CL
- Chile
- Prior art keywords
- peptides
- cancer immunotherapy
- peptide
- lymphocyte
- divisional
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
Abstract
La presente invención se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451255P | 2017-01-27 | 2017-01-27 | |
| DE102017101671 | 2017-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002461A1 true CL2021002461A1 (es) | 2022-06-24 |
Family
ID=61148200
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002093A CL2019002093A1 (es) | 2017-01-27 | 2019-07-26 | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer. |
| CL2020000817A CL2020000817A1 (es) | 2017-01-27 | 2020-03-30 | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer (divisional solicitud 201902093) |
| CL2021002461A CL2021002461A1 (es) | 2017-01-27 | 2021-09-22 | Péptido, anticuerpo y tcr que se unen al mismo, célula hospedadora, linfocito t activado, composición farmacéutica que los comprende, y sus usos en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) |
| CL2021002459A CL2021002459A1 (es) | 2017-01-27 | 2021-09-22 | Péptidos y combinaciones de péptidos para uso en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) |
| CL2021002460A CL2021002460A1 (es) | 2017-01-27 | 2021-09-22 | Péptidos, anticuerpos, tcr, célula hospedadora, linfocito t activado, composición farmacéutica, y sus usos en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) |
| CL2022002923A CL2022002923A1 (es) | 2017-01-27 | 2022-10-21 | Péptidos y sus combinaciones para uso en la inmunoterapia contra cáncer de ovario entre otros (solicitud divisional de 201902093) |
| CL2022003407A CL2022003407A1 (es) | 2017-01-27 | 2022-12-01 | Péptidos y sus combinaciones para uso en la inmunoterapia contra cáncer de ovario entre otros (solicitud divisional de 201902093) |
| CL2022003406A CL2022003406A1 (es) | 2017-01-27 | 2022-12-01 | Péptidos y sus combinaciones para uso en la inmunoterapia contra cáncer de ovario entre otros (solicitud divisional de 201902093) |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002093A CL2019002093A1 (es) | 2017-01-27 | 2019-07-26 | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer. |
| CL2020000817A CL2020000817A1 (es) | 2017-01-27 | 2020-03-30 | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer (divisional solicitud 201902093) |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002459A CL2021002459A1 (es) | 2017-01-27 | 2021-09-22 | Péptidos y combinaciones de péptidos para uso en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) |
| CL2021002460A CL2021002460A1 (es) | 2017-01-27 | 2021-09-22 | Péptidos, anticuerpos, tcr, célula hospedadora, linfocito t activado, composición farmacéutica, y sus usos en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) |
| CL2022002923A CL2022002923A1 (es) | 2017-01-27 | 2022-10-21 | Péptidos y sus combinaciones para uso en la inmunoterapia contra cáncer de ovario entre otros (solicitud divisional de 201902093) |
| CL2022003407A CL2022003407A1 (es) | 2017-01-27 | 2022-12-01 | Péptidos y sus combinaciones para uso en la inmunoterapia contra cáncer de ovario entre otros (solicitud divisional de 201902093) |
| CL2022003406A CL2022003406A1 (es) | 2017-01-27 | 2022-12-01 | Péptidos y sus combinaciones para uso en la inmunoterapia contra cáncer de ovario entre otros (solicitud divisional de 201902093) |
Country Status (23)
| Country | Link |
|---|---|
| US (10) | US11248035B1 (es) |
| EP (2) | EP3573647B1 (es) |
| JP (2) | JP7337695B2 (es) |
| KR (1) | KR20190112271A (es) |
| CN (1) | CN110198734A (es) |
| AU (6) | AU2018212584B2 (es) |
| BR (1) | BR112019015237A2 (es) |
| CA (1) | CA3048108A1 (es) |
| CL (8) | CL2019002093A1 (es) |
| CO (1) | CO2019008008A2 (es) |
| CR (4) | CR20210129A (es) |
| ES (1) | ES2946584T3 (es) |
| HR (1) | HRP20230512T8 (es) |
| IL (2) | IL299051A (es) |
| LT (1) | LT3573647T (es) |
| MX (1) | MX2019008843A (es) |
| NZ (1) | NZ754139A (es) |
| PE (1) | PE20191248A1 (es) |
| PH (1) | PH12019501377A1 (es) |
| RS (1) | RS64217B1 (es) |
| SG (2) | SG11201906198PA (es) |
| SI (1) | SI3573647T1 (es) |
| TW (1) | TW202325724A (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110857A1 (es) * | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| IL299051A (en) | 2017-01-27 | 2023-02-01 | Immatics Biotechnologies Gmbh | New peptides and their combinations for immunotherapy against ovarian cancer and other cancers |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| EP4298899A1 (en) | 2019-08-28 | 2024-01-03 | Dairycs Automatic Milking Ltd | A dairy farm with a single or multiple frontal elevated roads |
| CN110838372B (zh) * | 2019-11-18 | 2022-07-12 | 武汉大学 | 一种个性化癌症用药数据库***及建立方法 |
| CN111363744B (zh) * | 2020-02-26 | 2021-08-24 | 暨南大学 | 小檗碱介导的uhrf1基因抑制及其在制备治疗多发性骨髓瘤药物中的用途 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN114107502A (zh) * | 2021-11-29 | 2022-03-01 | 四川大学华西医院 | 一种上尿路上皮癌诊断标志物及其应用 |
| CN117210561A (zh) * | 2023-05-09 | 2023-12-12 | 山东第一医科大学第一附属医院(山东省千佛山医院) | Rnf106在食管鳞癌检测、治疗和预后靶点及应用 |
| CN116590263A (zh) * | 2023-07-02 | 2023-08-15 | 广州庆毅生物医药科技有限公司 | 一种重组蛋白、单克隆抗体及其检测试剂盒和应用 |
| CN117233393B (zh) * | 2023-11-15 | 2024-02-09 | 四川大学华西医院 | 双重免疫组化染色试剂盒及其在鉴别良恶性胆管上皮肿瘤中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998009638A1 (en) * | 1996-09-06 | 1998-03-12 | The Brigham And Women's Hospital, Inc. | INHIBITION OF MAST CELL ACTIVATION BY gp49-BASED MECHANISMS AND REAGENTS |
| US6514935B1 (en) * | 1997-03-14 | 2003-02-04 | President And Fellows Of Harvard | Methods of treating hypertension |
| GB0017512D0 (en) * | 2000-07-17 | 2000-08-30 | Smithkline Beecham Biolog | Novel compounds |
| WO2003014151A2 (en) * | 2001-08-10 | 2003-02-20 | Genset S.A. | Human secreted proteins, their encoding polynucleotides, and uses thereof |
| WO2003016475A2 (en) * | 2001-08-14 | 2003-02-27 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| US6906036B2 (en) * | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| CN1691964A (zh) * | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
| WO2005017102A2 (en) * | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| WO2005049073A2 (en) * | 2003-11-19 | 2005-06-02 | Survac Aps | Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
| US20090075832A1 (en) * | 2005-02-24 | 2009-03-19 | Cemines, Inc | Compositions and Methods for Classifying Biological Samples |
| EP1806359B1 (en) | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| CN106220721B (zh) * | 2007-03-26 | 2020-04-07 | 莱顿大学医学中心附属莱顿教学医院 | Prame衍生的肽以及包括该肽的免疫原组合物 |
| EP2562182B1 (en) | 2007-07-27 | 2015-10-07 | Immatics Biotechnologies GmbH | Novel immunogenic epitopes for immunotherapy |
| DK2280721T3 (da) * | 2008-04-17 | 2018-01-29 | Io Biotech Aps | Indoleamin-2, 3-dioxygenasebaseret immunterapi |
| SI2113253T1 (sl) * | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva |
| DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| WO2010037397A1 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| WO2012048291A2 (en) * | 2010-10-08 | 2012-04-12 | Proteapex Therapeutics Llc | Compositions and methods for inhibition of mmp:mmp-substrate interactions |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| IL299051A (en) | 2017-01-27 | 2023-02-01 | Immatics Biotechnologies Gmbh | New peptides and their combinations for immunotherapy against ovarian cancer and other cancers |
| AR110857A1 (es) * | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
-
2018
- 2018-01-26 IL IL299051A patent/IL299051A/en unknown
- 2018-01-26 LT LTEPPCT/EP2018/051952T patent/LT3573647T/lt unknown
- 2018-01-26 CR CR20210129A patent/CR20210129A/es unknown
- 2018-01-26 CR CR20190388A patent/CR20190388A/es unknown
- 2018-01-26 CA CA3048108A patent/CA3048108A1/en active Pending
- 2018-01-26 MX MX2019008843A patent/MX2019008843A/es unknown
- 2018-01-26 PE PE2019001476A patent/PE20191248A1/es unknown
- 2018-01-26 SG SG11201906198PA patent/SG11201906198PA/en unknown
- 2018-01-26 CR CR20210128A patent/CR20210128A/es unknown
- 2018-01-26 ES ES18702642T patent/ES2946584T3/es active Active
- 2018-01-26 SG SG10202108122YA patent/SG10202108122YA/en unknown
- 2018-01-26 EP EP18702642.2A patent/EP3573647B1/en active Active
- 2018-01-26 SI SI201830920T patent/SI3573647T1/sl unknown
- 2018-01-26 CR CR20210130A patent/CR20210130A/es unknown
- 2018-01-26 AU AU2018212584A patent/AU2018212584B2/en active Active
- 2018-01-26 RS RS20230396A patent/RS64217B1/sr unknown
- 2018-01-26 JP JP2019539937A patent/JP7337695B2/ja active Active
- 2018-01-26 TW TW112105929A patent/TW202325724A/zh unknown
- 2018-01-26 CN CN201880008006.XA patent/CN110198734A/zh active Pending
- 2018-01-26 HR HRP20230512TT patent/HRP20230512T8/hr unknown
- 2018-01-26 BR BR112019015237A patent/BR112019015237A2/pt unknown
- 2018-01-26 NZ NZ754139A patent/NZ754139A/en unknown
- 2018-01-26 KR KR1020197022277A patent/KR20190112271A/ko active IP Right Grant
- 2018-01-26 EP EP22151693.3A patent/EP4035675A3/en active Pending
-
2019
- 2019-06-17 PH PH12019501377A patent/PH12019501377A1/en unknown
- 2019-07-25 IL IL268278A patent/IL268278B2/en unknown
- 2019-07-25 CO CONC2019/0008008A patent/CO2019008008A2/es unknown
- 2019-07-26 CL CL2019002093A patent/CL2019002093A1/es unknown
-
2020
- 2020-03-30 CL CL2020000817A patent/CL2020000817A1/es unknown
-
2021
- 2021-03-02 AU AU2021201347A patent/AU2021201347A1/en active Pending
- 2021-03-02 AU AU2021201350A patent/AU2021201350B9/en active Active
- 2021-03-02 AU AU2021201349A patent/AU2021201349A1/en active Pending
- 2021-03-02 AU AU2021201346A patent/AU2021201346A1/en active Pending
- 2021-03-02 AU AU2021201348A patent/AU2021201348A1/en active Pending
- 2021-06-11 US US17/345,211 patent/US11248035B1/en active Active
- 2021-06-17 US US17/350,879 patent/US11858978B2/en active Active
- 2021-06-17 US US17/350,964 patent/US11214608B2/en active Active
- 2021-09-02 US US17/465,426 patent/US20230002474A1/en active Pending
- 2021-09-02 US US17/465,460 patent/US11345737B1/en active Active
- 2021-09-02 US US17/465,381 patent/US11919940B2/en active Active
- 2021-09-22 CL CL2021002461A patent/CL2021002461A1/es unknown
- 2021-09-22 CL CL2021002459A patent/CL2021002459A1/es unknown
- 2021-09-22 CL CL2021002460A patent/CL2021002460A1/es unknown
-
2022
- 2022-10-21 CL CL2022002923A patent/CL2022002923A1/es unknown
- 2022-12-01 CL CL2022003407A patent/CL2022003407A1/es unknown
- 2022-12-01 CL CL2022003406A patent/CL2022003406A1/es unknown
-
2023
- 2023-03-30 US US18/192,752 patent/US20240076349A1/en active Pending
- 2023-03-30 US US18/192,743 patent/US20240034769A1/en active Pending
- 2023-04-07 US US18/297,069 patent/US20230312680A1/en active Pending
- 2023-04-07 US US18/297,064 patent/US20230365651A1/en active Pending
- 2023-08-23 JP JP2023135232A patent/JP2023179415A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002461A1 (es) | Péptido, anticuerpo y tcr que se unen al mismo, célula hospedadora, linfocito t activado, composición farmacéutica que los comprende, y sus usos en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) | |
| CL2023001346A1 (es) | Uso de péptidos en inmunoterapia contra cáncer de pulmón amicrocítico y otros. | |
| CO2018008763A2 (es) | Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer | |
| CO2018010284A2 (es) | Tratamientos contra el cáncer de útero | |
| CL2018000780A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer | |
| CR20180245A (es) | Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer | |
| CL2021000842A1 (es) | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123) | |
| CO2019012077A2 (es) | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer | |
| CL2021000225A1 (es) | Inmunoterapia con péptidos restringidos a b*07 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| CO2021004270A2 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| CO2018012914A2 (es) | Péptidos y combinación de péptidos como dianas y para inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer | |
| CL2022000641A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres (divisional de la solicitud no. 202000020) | |
| CO2018012294A2 (es) | Inmunoterapia contra el melanoma y otros tipos de cáncer | |
| CO2021003404A2 (es) | Inmunoterapia con péptidos restringidos a a*01 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| CO2018004869A2 (es) | Péptidos y combinación de péptidos para inmunoterapia contra varios tipos de cáncer | |
| CL2020003371A1 (es) | Péptidos restringidos por a*03 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| CL2021000177A1 (es) | Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360) | |
| CL2020002935A1 (es) | Péptidos para el uso en la inmunoterapia contra el cáncer | |
| CL2021001336A1 (es) | Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| CL2021001011A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780) | |
| CO2017010830A2 (es) | Péptidos y combinaciones de péptidos y de soportes | |
| CL2021001525A1 (es) | Nuevos péptidos y nueva combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer (divisional de la solicitud no. 201803293) | |
| AR117437A1 (es) | Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados |